End of week links

Drug innovation and disease burden. Five lessons not learned from previous government shutdowns. “parents of daughters…become almost twice as risk-averse as parents of sons” Immigration and health care wait time in the US. Drug “kingpin captures cause large…increases to the homicide rate”


“The influence of referring physicians is dramatically greater than the effect of patient cost-sharing” Why is Obamacare enrollment down? One simple reason why value-based care may fail: poor patient attribution methods. MDMA for PTSD. Do veterans prefer VA or Medicare? Amazon Prime Health?

Your reading list

$25.5m verdict against Aetna. “New, simpler economic models” for PBMs Cost of ageism: $63 billion. What is the FDA doing about opioids? Value-based drug pricing in Michigan’s Medicaid program. Leading health care moneymakers. HRRP works in California. Access to pharmaceuticals in China.

Friday Links

Building bridges. Stents, the Shape Memory Effect and Superelasticity. Does digital lead to poor surgeons?W Will a drug work for you?  Can 23andMe really help answer this question? Utah-Mexico new medical tourism connection. Doing business. ACA reduced insurance disparities. FDA guidance on meta-analysis.


Treating cancer: the promise of IO combination therapy. FDA on developing drugs for rare diseases. CEA: v-thresholds vs. k-thresholds. Pharma fights back against PBMs by slashing prices? Debt to double by 2050? Sex workers over-report use of condoms. Are concerns over FDA’s “Pre-Cert for Software Pilot Program” justified? Moneyball in Medicare.